- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05312138
Multiple Sclerosis and Overactive Bladder Treatment
The Effect of Different Neuromodulation Techniques in the Treatment of Multiple Sclerosis Patients With Neurogenic Bladder Dysfunction
Study Overview
Status
Conditions
Detailed Description
Bladder dysfunction is one of the most disturbing symptoms of MS. The frequency of bladder dysfunction in patients with MS is reported to be %52-97. Urinary symptoms are among the initial symptoms in %10-15 of patients, while it is the only initial symptom in up to %2 of patients. Patients is seen with irritative symptoms (such as frequent urination, urgency, urinary incontinence, nocturia), obstructive symptoms (such as difficulty in initiating urination, inability to urinate, feeling of incomplete emptying, weak urine flow) or mixed type symptoms.In line with these symptoms, early evaluation of MS patients in terms of urinary system, planning of appropriate treatment and regular follow-up are extremely important in terms of preventing urinary system complications. Pharmacotherapy and clean intermittent catheterization are the first step treatments for lower urinary tract symptoms in multiple sclerosis. It has been reported in the literature that electrical nerve stimulation therapy (neuromodulation methods) and behavior change methods (pelvic floor muscle exercise, bladder training, urinary diary keeping) are also used as a second step treatment option due to the side effects of anticholinergic use and lack of motivation and skill in catheterization. It is reported that neuromodulation applications are performed in MS patients and it is a reliable method. Deep brain stimulation, transcranial magnetic stimulation, posterior tibial nerve stimulation, sacral neuromodulation and spinal cord stimulation are generally recommended in the treatment of bladder dysfunction, which is one of the neuromodulation methods. The superiority of these methods to each other is debatable. In line with this information, the aim of the study is to compare the effectiveness of different neuromodulation techniques, transcutaneous posterior tibial nerve stimulation and repetitive transcranial magnetic stimulation, in MS patients reporting lower urinary tract symptoms.
According to the treatment protocols of the patients to be included in the study; will be divided into 2 groups as transcutaneous posterior tibial nerve stimulation group (8 patients) and repetitive transcranial magnetic stimulation group (8 patients). Which method will be applied to which individual will be determined randomly. Treatment sessions will be carried out for 5 consecutive days in 2 consecutive weeks, 1 time per day for a total of 10 sessions. The urological parameters of the patients in all groups will be evaluated before and after the treatment.
Statistical method(s); Statistical analysis of the data obtained from the study will be done in the Statistical Package for the Social Sciences (SPSS) 22.0 package program. The mean standard deviation, median, minimum and maximum values will be used to define the data. Comparison of continuous variables between groups will be done with Mann Whitney U test, comparison of discrete variables will be done with chi-square test. Spearman or Pearson correlation test will be used to evaluate the correlation between variables. In the data analysis, p < 0.05 level will be considered statistically significant.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey
- Istanbul Medipol Mega University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-65 years old
- Woman
- Volunteer to participate in the study
- Neurogenic overactive bladder due to MS
- EDSS <7.0
- Not benefiting from pharmacological treatment
Exclusion Criteria:
- With urinary tract infection
- Diagnosed with diabetes mellitus
- Using diuretic medication
- Using clean intermittent catheterization
- Having a history of different urological diseases
- Those who have conditions that would be contraindicated for electrical stimulation (pacemaker, brain pacemaker, prosthesis)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transcutaneous Posterior Tibial Nerve Stimulation Group
The treatment will be carried out by the physiotherapist using the TenStem Eco Basic device.
|
The treatment parameters will be applied with a pulse current time of 200 μsec, a fixed frequency of 10 Hz, a treatment time of 20 minutes, and a current intensity that the patient can tolerate, which will not cause flexion in the big toe or fan movement in the other fingers.
Self-adhesive surface electrodes will be used for stimulation.
During the treatment, the patient will lie on his back.
The negative electrode will be placed 2 cm posterior to the medial malleolus and the positive electrode will be placed 10 cm proximal.
|
Active Comparator: Repetitive Transcranial Magnetic Stimulation Group
The treatment will be applied with a Power Mag device.
|
The treatment will be internally cooled 70 mm double coil and 110 mm round coil, accompanied by a physiotherapist and neurologist.
The coil will be placed on the precentral gyrus.
Practices will be held, with each session lasting 20 minutes.
Cortical excitability will be provided by high frequency (HF) stimulation (5-Hz).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urodynamics Test
Time Frame: "10 days" the amount of change after 10 days from the baseline
|
While the bladder is being filled, it will be carried out to measure the pressures in the bladder and in the abdomen, to examine the nerves that provide bladder contractions, and to explain the cases of urinary incontinence or inability by examining the bladder contraction pressures and electrical activity during urination.
|
"10 days" the amount of change after 10 days from the baseline
|
Extended Disability Status Scale (EDSS)
Time Frame: "10 days" the amount of change after 10 days from the baseline
|
It is the most commonly used scale to assess disability in MS.
EDSS scoring is based on the neurological examination results of eight functional systems and the patient's ambulation status.
Functional systems are listed as pyramidal, cerebellar, brainstem, sensory, bladder and intestinal, visual, cerebral, and others.
A score of 0-10 is given.0
denotes normal neurological examination, 10 denotes death due to MS. 1.0-4.5 refers to fully ambulatory, 5.0-9.5 refers to impaired ambulation.
From 7.0 onwards there is wheelchair use and increasingly bed dependency.
|
"10 days" the amount of change after 10 days from the baseline
|
Overactive Bladder Questionnaire-V8 (OAB-V8)
Time Frame: "10 days" the amount of change after 10 days from the baseline
|
The severity of the patients' complaints, none (0); very few (1); a little (2); quite a few (3); many (4); and too many (5) it consists of 8 questions that can be graded.
The total score can vary between 0 and 40.
|
"10 days" the amount of change after 10 days from the baseline
|
Incontinence Quality of Life -I-QOL
Time Frame: "10 days" the amount of change after 10 days from the baseline
|
It consists of a total of 22 questions with three sub-dimensions.
Sub-dimensions; limitation of behaviors (1,2,3,4,10,11,13,20 items), psychosocial influence (5,6,7,9,15,16,17,21,22 items) and social isolation (8,12 ,14,18,19 items).
All items are evaluated with a five-point Likert type (1= too much, 2= a quite, 3= moderately, 4= a little, 5= not at all) and the Likert types are recalculated to take a value between 0-100 points in order to better understand the total score calculated.
Higher scores indicate better quality of life.
|
"10 days" the amount of change after 10 days from the baseline
|
Voiding Diary
Time Frame: "10 days" the amount of change after 10 days from the baseline
|
It is recommended to present the information given by the patients in an objective way.
Although not entirely diagnostic, diary data can reveal normal and abnormal conditions.
The 3-day voiding diary is a viable, reliable and valid tool in the evaluation of patients with lower urinary tract symptoms.
|
"10 days" the amount of change after 10 days from the baseline
|
Incontinence Severity Index (ISI)
Time Frame: "10 days" the amount of change after 10 days from the baseline
|
It consists of 2 questions, and the total score is obtained by multiplying the frequency of urinary incontinence and the amount of urine leaked, and the score range varies between 1-12.
According to their score, 1-2 points are light; 3-6 points average; 8-9 points indicate severe and 12 points very severe urinary incontinence.
|
"10 days" the amount of change after 10 days from the baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Pınar Atak Çakır
Publications and helpful links
General Publications
- de Seze M, Raibaut P, Gallien P, Even-Schneider A, Denys P, Bonniaud V, Game X, Amarenco G. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn. 2011 Mar;30(3):306-11. doi: 10.1002/nau.20958. Epub 2011 Feb 8.
- Nardone R, Versace V, Sebastianelli L, Brigo F, Golaszewski S, Christova M, Saltuari L, Trinka E. Transcranial magnetic stimulation and bladder function: A systematic review. Clin Neurophysiol. 2019 Nov;130(11):2032-2037. doi: 10.1016/j.clinph.2019.08.020. Epub 2019 Sep 3.
- Abboud H, Hill E, Siddiqui J, Serra A, Walter B. Neuromodulation in multiple sclerosis. Mult Scler. 2017 Nov;23(13):1663-1676. doi: 10.1177/1352458517736150.
- Fingerman JS, Finkelstein LH. The overactive bladder in multiple sclerosis. J Am Osteopath Assoc. 2000 Mar;100(3 Suppl):S9-12.
- Atak Cakir P, Mutluay F, Hanoglu L, Guzelburc V. Effect of transcutaneous posterior tibial nerve stimulation and repetitive transcranial magnetic stimulation on neurogenic overactive bladder symptoms in female patients with multiple sclerosis: The study protocol of a randomized controlled study. Front Neurol. 2022 Oct 28;13:1011502. doi: 10.3389/fneur.2022.1011502. eCollection 2022.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Urologic Diseases
- Urinary Bladder Diseases
- Neurologic Manifestations
- Multiple Sclerosis
- Sclerosis
- Urinary Bladder, Neurogenic
Other Study ID Numbers
- patak
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurogenic Bladder Dysfunction
-
Ulrich MehnertNCCR (National Center of Competence in Resaerch, Switzerland)CompletedHealthy | Neurogenic Bladder Dysfunction Nos | Nonneurogenic Neurogenic Bladder DysfunctionSwitzerland
-
Novartis PharmaceuticalsTerminatedNeurogenic Urinary Bladder | Neurogenic Bladder Disorder | Neurogenic Dysfunction of the Urinary Bladder | Neurogenic Bladder, Uninhibited | Neurogenic Bladder, SpasticNetherlands, Germany, Switzerland
-
University of ZurichTerminatedNeurogenic Bladder DysfunctionSwitzerland
-
APOGEPHA Arzneimittel GmbHCompletedUrologic Diseases | Urinary Incontinence | Urinary Bladder, Neurogenic | Neurogenic Urinary Bladder Disorder | Bladder Disorder, Neurogenic | Urinary Bladder Disorder, Neurogenic | Neurogenic Bladder Disorder | Urinary Bladder Neurogenic Dysfunction | Overactive Detrusor FunctionRomania, Austria, Germany
-
Swiss Paraplegic Centre NottwilCompletedNeurogenic Bladder DysfunctionSwitzerland
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingImmunosuppression | Neurogenic Bladder | Bladder DysfunctionUnited States
-
Coloplast A/SCompletedNeurogenic Bladder Dysfunction NosDenmark, France, Germany, Norway, Sweden
-
JW PharmaceuticalCompletedNeurogenic Bladder | Voiding DysfunctionKorea, Republic of
-
The Methodist Hospital Research InstituteCompleted
-
University of ZurichRecruitingNeurogenic Bladder DysfunctionBelgium, Brazil, Italy, Switzerland
Clinical Trials on Transcutaneous Posterior Tibial Nerve Stimulation
-
London North West Healthcare NHS TrustUroplasty, IncUnknown
-
Boston Medical GroupCompleted
-
Hospital de Clinicas de Porto AlegreUnknownOveractive Bladder | Urinary Urge IncontinenceBrazil
-
Glasgow Caledonian UniversityNational Institute for Health Research, United KingdomUnknownUrinary IncontinenceUnited Kingdom
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalRecruitingMultiple Sclerosis | Lower Urinary Tract SymptomsTurkey
-
Hospital Universitari Vall d'Hebron Research InstituteInstituto de Salud Carlos IIICompletedColorectal SurgerySpain
-
Innovacion en Cirugía VigoRecruitingLow Anterior Resection Syndrome | Rectal Disorders | Low Anterior ResectionSpain
-
Lawson Health Research InstituteCompleted
-
Batterjee Medical CollegeBenha UniversityCompletedFecal IncontinenceEgypt
-
Massachusetts General HospitalTerminatedFecal IncontinenceUnited States